BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22069350)

  • 1. Ocular onchocerciasis: current management and future prospects.
    Babalola OE
    Clin Ophthalmol; 2011; 5():1479-91. PubMed ID: 22069350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis.
    Abegunde AT; Ahuja RM; Okafor NJ
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011146. PubMed ID: 26771164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research for new drugs for elimination of onchocerciasis in Africa.
    Kuesel AC
    Int J Parasitol Drugs Drug Resist; 2016 Dec; 6(3):272-286. PubMed ID: 27693536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of transmission of onchocerciasis (river blindness) with long-term ivermectin mass drug administration with or without vector control in sub-Saharan Africa: a systematic review and meta-analysis.
    Mutono N; Basáñez MG; James A; Stolk WA; Makori A; Kimani TN; Hollingsworth TD; Vasconcelos A; Dixon MA; de Vlas SJ; Thumbi SM
    Lancet Glob Health; 2024 May; 12(5):e771-e782. PubMed ID: 38484745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment and monitoring of onchocerciasis in Latin America.
    Rodríguez-Pérez MA; Unnasch TR; Real-Najarro O
    Adv Parasitol; 2011; 77():175-226. PubMed ID: 22137585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxidectin: an oral treatment for human onchocerciasis.
    Milton P; Hamley JID; Walker M; Basáñez MG
    Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1067-1081. PubMed ID: 32715787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of onchocerciasis.
    Boatin BA; Richards FO
    Adv Parasitol; 2006; 61():349-94. PubMed ID: 16735169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final report of the Conference on the eradicability of Onchocerciasis.
    Dadzie Y; Neira M; Hopkins D
    Filaria J; 2003 Feb; 2(1):2. PubMed ID: 12605722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of test-and-treat with doxycycline and temephos ground larviciding as alternative strategies for accelerating onchocerciasis elimination in an area of loiasis co-endemicity: the COUNTDOWN consortium multi-disciplinary study protocol.
    Wanji S; Nji TM; Hamill L; Dean L; Ozano K; Njouendou AJ; Abong RA; Obie ED; Amuam A; Ekanya R; Ndongmo WPC; Ndzeshang BL; Fung EG; Nnamdi DB; Nkimbeng DA; Teghen S; Kah E; Piotrowski H; Forrer A; Khan JAM; Woode ME; Niessen L; Watson V; Njoumemi Z; Murdoch ME; Thomson R; Theobald S; Enyong P; Turner JD; Taylor MJ
    Parasit Vectors; 2019 Dec; 12(1):574. PubMed ID: 31801631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Onchocerciasis Elimination Program for the Americas (OEPA).
    Sauerbrey M
    Ann Trop Med Parasitol; 2008 Sep; 102 Suppl 1():25-9. PubMed ID: 18718151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Mectizan Donation Program (MDP).
    Thylefors B
    Ann Trop Med Parasitol; 2008 Sep; 102 Suppl 1():39-44. PubMed ID: 18718154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world.
    Nicholls RS; Duque S; Olaya LA; López MC; Sánchez SB; Morales AL; Palma GI
    Parasit Vectors; 2018 Apr; 11(1):237. PubMed ID: 29642939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reaching the last mile: main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa.
    Gebrezgabiher G; Mekonnen Z; Yewhalaw D; Hailu A
    Infect Dis Poverty; 2019 Jul; 8(1):60. PubMed ID: 31269966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of onchocerciasis and associated clinical manifestations in selected hypoendemic communities in Ghana following long-term administration of ivermectin.
    Otabil KB; Gyasi SF; Awuah E; Obeng-Ofori D; Atta-Nyarko RJ; Andoh D; Conduah B; Agbenyikey L; Aseidu P; Ankrah CB; Nuhu AR; Schallig HDFH
    BMC Infect Dis; 2019 May; 19(1):431. PubMed ID: 31101085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards the elimination of onchocerciasis.
    Thylefors B; Alleman M
    Ann Trop Med Parasitol; 2006 Dec; 100(8):733-46. PubMed ID: 17227651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of ivermectin to human onchocerciasis: past, present, and the future.
    Cupp EW; Mackenzie CD; Unnasch TR
    Res Rep Trop Med; 2011; 2():81-92. PubMed ID: 30881181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
    Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
    Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy.
    Cupp EW; Sauerbrey M; Richards F
    Acta Trop; 2011 Sep; 120 Suppl 1():S100-8. PubMed ID: 20801094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onchocerciasis and other eye problems in developing countries: a challenge for optometrists.
    Berger IB; Nnadozie J
    J Am Optom Assoc; 1993 Oct; 64(10):699-702. PubMed ID: 8245390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivermectin for onchocercal eye disease (river blindness).
    Ejere HO; Schwartz E; Wormald R; Evans JR
    Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD002219. PubMed ID: 22895928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.